Literature DB >> 9107610

Primer on medical decision analysis: Part 5--Working with Markov processes.

D Naimark1, M D Krahn, G Naglie, D A Redelmeier, A S Detsky.   

Abstract

Clinical decisions often have long-term implications. Analysis encounter difficulties when employing conventional decision-analytic methods to model these scenarios. This occurs because probability and utility variables often change with time and conventional decision trees do not easily capture this dynamic quality. A Markov analysis performed with current computer software programs provides a flexible and convenient means of modeling long-term scenarios. However, novices should be aware of several potential pitfalls when attempting to use these programs. When deciding how to model a given clinical problem, the analyst must weigh the simplicity and clarity of a conventional tree against the fidelity of a Markov analysis. In direct comparisons, both approaches gave the same qualitative answers.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9107610     DOI: 10.1177/0272989X9701700205

Source DB:  PubMed          Journal:  Med Decis Making        ISSN: 0272-989X            Impact factor:   2.583


  39 in total

Review 1.  Benefit-risk analysis : a brief review and proposed quantitative approaches.

Authors:  William L Holden
Journal:  Drug Saf       Date:  2003       Impact factor: 5.606

2.  Should risky treatments be reserved for secondary prevention? Theoretical considerations regarding risk-benefit tradeoffs.

Authors:  M Brandon Westover; Nathaniel A Eiseman; Matt T Bianchi
Journal:  J Clin Epidemiol       Date:  2012-05-27       Impact factor: 6.437

3.  The development of a decision analytic model of changes in mean deviation in people with glaucoma: the COA model.

Authors:  Steven M Kymes; Dennis L Lambert; Paul P Lee; David C Musch; Carla J Siegfried; Sameer V Kotak; Dustin L Stwalley; Joel Fain; Chris Johnson; Mae O Gordon
Journal:  Ophthalmology       Date:  2012-04-25       Impact factor: 12.079

Review 4.  Management of solitary 1 cm to 2 cm liver nodules in patients with compensated cirrhosis: a decision analysis.

Authors:  Karen E Bremner; Ahmed M Bayoumi; Morris Sherman; Murray D Krahn
Journal:  Can J Gastroenterol       Date:  2007-08       Impact factor: 3.522

5.  Radiofrequency ablation plus nucleotide analogous for hepatitis B virus-related hepatocellular carcinoma: a cost-effectiveness analysis.

Authors:  Baoxian Liu; Mengchao Wei; Furong Liu; Shuling Chen; Zhenwei Peng; Bin Li; Qian Zhou; Haibo Wang; Sui Peng; Ming Kuang
Journal:  Am J Transl Res       Date:  2018-08-15       Impact factor: 4.060

6.  Economic impact assessment from the use of a mobile app for the self-management of heart diseases by patients with heart failure in a Spanish region.

Authors:  José Antonio Cano Martín; Borja Martínez-Pérez; Isabel de la Torre-Díez; Miguel López-Coronado
Journal:  J Med Syst       Date:  2014-07-04       Impact factor: 4.460

7.  Management of biliary tract disease during pregnancy: a decision analysis.

Authors:  Eric B Jelin; Douglas S Smink; Ashley H Vernon; David C Brooks
Journal:  Surg Endosc       Date:  2007-08-23       Impact factor: 4.584

8.  Quantitative risk-benefit analysis of natalizumab.

Authors:  J P Thompson; K Noyes; E R Dorsey; S R Schwid; R G Holloway
Journal:  Neurology       Date:  2008-07-29       Impact factor: 9.910

Review 9.  Optimal management of colorectal liver metastases in older patients: a decision analysis.

Authors:  Simon Yang; Shabbir M H Alibhai; Erin D Kennedy; Abraham El-Sedfy; Matthew Dixon; Natalie Coburn; Alex Kiss; Calvin H L Law
Journal:  HPB (Oxford)       Date:  2014-06-24       Impact factor: 3.647

10.  An economic evaluation of venous thromboembolism prophylaxis strategies in critically ill trauma patients at risk of bleeding.

Authors:  T Carter Chiasson; Braden J Manns; Henry Thomas Stelfox
Journal:  PLoS Med       Date:  2009-06-23       Impact factor: 11.069

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.